vtioВестник трансплантологии и искусственных органовRussian Journal of Transplantology and Artificial Organs1995-1191Academician V.I.Shumakov National Medical Research Center of Transplantology and Artificial Organs", Ministry of Health of the Russian Federation10.15825/1995-1191-2009-4-110-117vtio-278Research ArticleОбзор литературыLiterature ReviewsТРАНСПЛАНТАЦИЯ ПЕЧЕНИ И HBV-ИНФЕКЦИЯLIVER TRANSPLANTATION AND HBV INFECTIONАндрейцеваО. И.AndreytsevaO. I.olga-lte@rambler.ruКозловаА. В.KozlovaA. V.СюткинВ. Е.SutkinV. E.НИИ СП им. Н.В. Склифосовского, МоскваРоссияN.V. Sklifosovsky Recearch Institute for emergency, MoscowRussian Federation200903062014114ВЕСТНИК ТРАНСПЛАНТОЛОГИИ И ИСКУССТВЕННЫХ ОРГАНОВ том XI No 4–2009110117Copyright © Андрейцева О.И., Козлова А.В., Сюткин В.Е., 20092009Андрейцева О.И., Козлова А.В., Сюткин В.Е.Andreytseva O.I., Kozlova A.V., Sutkin V.E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.transpl.ru/vtio/article/view/278

В статье представлены современные данные по трансплантации печени при HBV-инфекции. Показано, что пациенты с циррозом печени HBV-этиологии, ожидающие трансплантации печени, должны длитель- но получать аналоги нуклеоз(т)идов вплоть до ОТП. Обсуждаются различные схемы профилактики воз- вратной HBV-инфекции в посттрансплантационном периоде и специфическое лечение de novo гепатита В после ОТП, возможность выполнения ОТП пациентам с ГЦР в исходе цирроза печени HBV-этиологии. 

The paper describes the modern approaches in treatment of hepatitis B virus (HBV)-infected patients who underwent liver transplantation. The patients with HBV liver cirrhosis and waiting for orthotopic liver transplantation (OLT) have to receive long-term therapy with nucleos(t)ide analogs right up to liver transplantation. The paper discuss the different schemes of prophylaxis of recurrent HBV infection during post-transplantation and specific treatment of HBV infection after liver transplantation as well as possibilities of orthotopic liver transplantation for patients with liver cancer. 

трансплантация печенивозвратная HBV-инфекцияde novo гепатит Виммуноглобулин против гепатита В (HBIg)ламивудинэнтекавирliver transplantationrecurrent HBV infectionde novo hepatitis Bimmunoglobulin against HBV (HBIg)lamivudineentecavirReferencesШерлок Ш., Дули Д. Рецидив болезни // Заболевания пе- чени и желчных путей. М.: ГЭОТАР Медицина, 1999. С. 756.Шерлок Ш., Дули Д. Рецидив болезни // Заболевания пе- чени и желчных путей. М.: ГЭОТАР Медицина, 1999. С. 756.Angelico M., Di Paolo D., Trinito M.O. et al. Failure of a reinforced triple course of hepatitis B vaccination in pa- tients transplanted for HBV-related cirrhosis // Hepatology. 2002. Vol. 35. P. 176–181.Angelico M., Di Paolo D., Trinito M.O. et al. Failure of a reinforced triple course of hepatitis B vaccination in pa- tients transplanted for HBV-related cirrhosis // Hepatology. 2002. Vol. 35. P. 176–181.Angus P.W., McCaughan G.W., Gane E.J. et al. Combina- tion low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttrans- plantation hepatitis B // Liver Transpl. 2000. Vol. 6. P. 429– 433.Angus P.W., McCaughan G.W., Gane E.J. et al. Combina- tion low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttrans- plantation hepatitis B // Liver Transpl. 2000. Vol. 6. P. 429– 433.Angus P.W., Patterson S.J., Strasser S.I. et al. A randomized study of adefovir dipivoxil in place of HBIG in combina- tion with lamivudine as post-liver transplantation hepatitis B prophylaxis // Hepatology. 2008. Vol. 48. P. 1460–1466.Angus P.W., Patterson S.J., Strasser S.I. et al. A randomized study of adefovir dipivoxil in place of HBIG in combina- tion with lamivudine as post-liver transplantation hepatitis B prophylaxis // Hepatology. 2008. Vol. 48. P. 1460–1466.Barcena R., Moraleda G., Moreno J. et al. Prevention of de novo HBV infection by the presence of anti-HBs in trans- planted patients receiving core antibody-positive livers // World J. Gastroenterol. 2006. Vol. 7; 12 (13). P. 2070– 2074.Barcena R., Moraleda G., Moreno J. et al. Prevention of de novo HBV infection by the presence of anti-HBs in trans- planted patients receiving core antibody-positive livers // World J. Gastroenterol. 2006. Vol. 7; 12 (13). P. 2070– 2074.Buti M., Mas A., Prieto M. et al. A randomized study com- paring lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepa- titis B virus recurrence after liver transplantation // J. Hepa- tol. 2003. Vol. 38. P. 811–817.Buti M., Mas A., Prieto M. et al. A randomized study com- paring lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepa- titis B virus recurrence after liver transplantation // J. Hepa- tol. 2003. Vol. 38. P. 811–817.Cahlin C., Olausson M., Friman S. Severe clinical course of de novo hepatitis B infection after liver transplantation // Transplant. Proc. 2001. Vol. 33 (4). P. 2467–2468.Cahlin C., Olausson M., Friman S. Severe clinical course of de novo hepatitis B infection after liver transplantation // Transplant. Proc. 2001. Vol. 33 (4). P. 2467–2468.Castells L., Esteban R. Hepatitis B vaccination in liver transplant candidates // Eur. J. Gastroenterol. Hepatol. 2001. Vol. 13 (4). P. 359–361.Castells L., Esteban R. Hepatitis B vaccination in liver transplant candidates // Eur. J. Gastroenterol. Hepatol. 2001. Vol. 13 (4). P. 359–361.Castells L., Vargas V., Rodríguez F. et al. Clinical impact and efficacy of lamivudine therapy in de novo hepatitis B infection after liver transplantation // Liver Transpl. 2002. Vol. 8 (10). P. 892–900.Castells L., Vargas V., Rodríguez F. et al. Clinical impact and efficacy of lamivudine therapy in de novo hepatitis B infection after liver transplantation // Liver Transpl. 2002. Vol. 8 (10). P. 892–900.Chazouilleres O., Mamish D., Kim M. et al. «Occult» hepa- titis B virus as source of infection in liver transplant reci- pients // Lancet. 1994. Vol. 343 (8890). P. 142–146.Chazouilleres O., Mamish D., Kim M. et al. «Occult» hepa- titis B virus as source of infection in liver transplant reci- pients // Lancet. 1994. Vol. 343 (8890). P. 142–146.Crespo J., Fábrega E., Casafont F. et al. Severe clinical course of de novo hepatitis B infection after liver trans- plantation // Liver Transpl. Surg. 1999. No 5 (3). P .175– 183.Crespo J., Fábrega E., Casafont F. et al. Severe clinical course of de novo hepatitis B infection after liver trans- plantation // Liver Transpl. Surg. 1999. No 5 (3). P .175– 183.Degertekin B., Lok A.F. Hepatocellular Carcinoma (HCC) is the main Indication for Liver Transplantation (OLT) among HBV Patients in the era of Nucleos/tide Analogue Therapies, 59th AASLD Meeting, October 31-November 4, 2008, San Francisco, USA // Hepatology. 2008; 48 (abstract 1437).Degertekin B., Lok A.F. Hepatocellular Carcinoma (HCC) is the main Indication for Liver Transplantation (OLT) among HBV Patients in the era of Nucleos/tide Analogue Therapies, 59th AASLD Meeting, October 31-November 4, 2008, San Francisco, USA // Hepatology. 2008; 48 (abstract 1437).Dickson R.C., Everhart J.E., Lake J.R. et al. Transmission of hepatitis B by transplantation of livers from donors posi- tive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database // Gastroenterology. 1997. Vol. 113 (5). P. 1668–1674.Dickson R.C., Everhart J.E., Lake J.R. et al. Transmission of hepatitis B by transplantation of livers from donors posi- tive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database // Gastroenterology. 1997. Vol. 113 (5). P. 1668–1674.Dodson S.F., de Vera M.E., Bonham C.A. et al. Lamivudine after hepatitis B immune globulin is effective in preventing hepatitis B recurrence after liver transplantation // Liver Transpl. 2000. Vol. 6. P. 434–439.Dodson S.F., de Vera M.E., Bonham C.A. et al. Lamivudine after hepatitis B immune globulin is effective in preventing hepatitis B recurrence after liver transplantation // Liver Transpl. 2000. Vol. 6. P. 434–439.Douglas D.D., Rakela J., Taswell H. et al. Transmission of hepatitis B virus infection from orthtopic donor livers [ab- stract] // Hepatology. 1992. Vol. 16. P. 49A.Douglas D.D., Rakela J., Taswell H. et al. Transmission of hepatitis B virus infection from orthtopic donor livers [ab- stract] // Hepatology. 1992. Vol. 16. P. 49A.Douglas D.D., Rakela J., Wright T.L. et al. The clinical course of transplantation-associated de novo hepatitis B infection in the liver transplant recipient // Liver Transpl. Surg. 1997. Vol. 3 (2). P. 105–111.Douglas D.D., Rakela J., Wright T.L. et al. The clinical course of transplantation-associated de novo hepatitis B infection in the liver transplant recipient // Liver Transpl. Surg. 1997. Vol. 3 (2). P. 105–111.Fabia R., Levy M., Crippin J. et al. De novo hepatitis B infection after liver transplantation: sources of disease, in- cidence and impact // Liver. Transpl. Surg. 1997. Vol. 4. P. 119–127.Fabia R., Levy M., Crippin J. et al. De novo hepatitis B infection after liver transplantation: sources of disease, in- cidence and impact // Liver. Transpl. Surg. 1997. Vol. 4. P. 119–127.Gane E.J., Angus P.W., Strasser S. et al. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation // Gastroentero- logy. 2007. Vol. 132. P. 931–937.Gane E.J., Angus P.W., Strasser S. et al. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation // Gastroentero- logy. 2007. Vol. 132. P. 931–937.Grellier L., Mutimer D., Ahmed M. et al. Lamivudine prop- hylaxis against reinfection in liver transplantation for hepa- titis В cirrhosis // Lancet. l996. Vol. 348. P. 1212–1215.Grellier L., Mutimer D., Ahmed M. et al. Lamivudine prop- hylaxis against reinfection in liver transplantation for hepa- titis В cirrhosis // Lancet. l996. Vol. 348. P. 1212–1215.Hussain M., Soldevila-Pico C., Emre S. et al. Presence of intrahepatic (total and ccc) HBV DNA is not predictive of HBV recurrence after liver transplantation // Liver Transpl. 2007. Vol. 13. P. 1137–1144.Hussain M., Soldevila-Pico C., Emre S. et al. Presence of intrahepatic (total and ccc) HBV DNA is not predictive of HBV recurrence after liver transplantation // Liver Transpl. 2007. Vol. 13. P. 1137–1144.Hwang S., Lee S.G., Ahn C.S. et al. Prevention of hepati- tis B recurrence after living donor liver transplantation: pri- mary high-dose hepatitis B immunoglobulin monotherapy and rescue antiviral therapy // Liver Transpl. 2008. Vol. 14. P. 770–778.Hwang S., Lee S.G., Ahn C.S. et al. Prevention of hepati- tis B recurrence after living donor liver transplantation: pri- mary high-dose hepatitis B immunoglobulin monotherapy and rescue antiviral therapy // Liver Transpl. 2008. Vol. 14. P. 770–778.Jiao Z.Y., Jiao Z. Prophylaxis of recurrent hepatitis B in Chinese patients after liver transplantation using lamivudi- ne combined with hepatitis B immune globulin according to the titer of antibody to hepatitis B surface antigen // Trans- plant. Proc. 2007. Vol. 39. P. 1533–1536.Jiao Z.Y., Jiao Z. Prophylaxis of recurrent hepatitis B in Chinese patients after liver transplantation using lamivudi- ne combined with hepatitis B immune globulin according to the titer of antibody to hepatitis B surface antigen // Trans- plant. Proc. 2007. Vol. 39. P. 1533–1536.Jiao Z.Y., Yan L.N., Li B. et al. Liver transplantation for chronic hepatitis B patients with lamivudine monotherapy or lamivudine combined with individualized low-dose he- patitis B immunoglobulin treatment // Zhonghua Ganzang- bing Zazhi. 2007. Vol. 15. P. 804–808.Jiao Z.Y., Yan L.N., Li B. et al. Liver transplantation for chronic hepatitis B patients with lamivudine monotherapy or lamivudine combined with individualized low-dose he- patitis B immunoglobulin treatment // Zhonghua Ganzang- bing Zazhi. 2007. Vol. 15. P. 804–808.Karademir S., Astarcioglu H., Akarsu M. et al. Prophylactic use of low-dose, on-demand, intramuscular hepatitis B im- munoglobulin and lamivudine after liver transplantation // Transplant. Proc. 2006. Vol. 38. P. 579–583.Karademir S., Astarcioglu H., Akarsu M. et al. Prophylactic use of low-dose, on-demand, intramuscular hepatitis B im- munoglobulin and lamivudine after liver transplantation // Transplant. Proc. 2006. Vol. 38. P. 579–583.Kim K.K., Kim K.H., Hwang S. et al. Therapeutic effect of adefovir dipivoxil on recurrent or de novo infection of hepatitis B virus after liver transplantation: a preliminary report. Article in Korean // Korean. J. Gastroenterol. 2005. Vol. 45 (3). P. 174–180.Kim K.K., Kim K.H., Hwang S. et al. Therapeutic effect of adefovir dipivoxil on recurrent or de novo infection of hepatitis B virus after liver transplantation: a preliminary report. Article in Korean // Korean. J. Gastroenterol. 2005. Vol. 45 (3). P. 174–180.Lampertico P., Viganò M., Donato M. et al. Excellent 5-year overall survival in patients with HBV-related cirrhosis un- dergoing transplantation for hepatocellular carcinoma, 59th AASLD Meeting, October 31-November 4, 2008, San Fran- cisco, USA // Hepatology. 2008. Vol. 48 (abstract 621).Lampertico P., Viganò M., Donato M. et al. Excellent 5-year overall survival in patients with HBV-related cirrhosis un- dergoing transplantation for hepatocellular carcinoma, 59th AASLD Meeting, October 31-November 4, 2008, San Fran- cisco, USA // Hepatology. 2008. Vol. 48 (abstract 621).Lauchart W., Muller R., Pichlmayr R. Long-term immunopro- phylaxis of hepatitis B virus reinfection in recipients of human liver allografts // Transplant. Proc. 1987. Vol. 19. P. 4051–4053.Lauchart W., Muller R., Pichlmayr R. Long-term immunopro- phylaxis of hepatitis B virus reinfection in recipients of human liver allografts // Transplant. Proc. 1987. Vol. 19. P. 4051–4053.Li Jiang, Li-Sheng Jiang, Nan-Sheng Cheng and Lu-Nan Yan. Current prophylactic strategies against hepatitis B vi- rus recurrence after liver transplantation // World. J. Gas- troenterol. 2009 May 28. No 15 (20). Р. 2489–2499.Li Jiang, Li-Sheng Jiang, Nan-Sheng Cheng and Lu-Nan Yan. Current prophylactic strategies against hepatitis B vi- rus recurrence after liver transplantation // World. J. Gas- troenterol. 2009 May 28. No 15 (20). Р. 2489–2499.Limquiaco J.L., Wong J., Wong V.W. et al. Lamivudine mo- noprophylaxis and adefovir salvage for liver transplantation in chronic hepatitis B: a seven-year follow-up study // J. Med. Virol. 2009. Vol. 81. Р. 224–229.Limquiaco J.L., Wong J., Wong V.W. et al. Lamivudine mo- noprophylaxis and adefovir salvage for liver transplantation in chronic hepatitis B: a seven-year follow-up study // J. Med. Virol. 2009. Vol. 81. Р. 224–229.Lo C.M., Cheung S.T., Lai C.L. et al. Liver transplantation in Asian patients with chronic hepatitis В using lamivudine prophylaxis // Ann. Surg. 2001. Vol. 233. Р. 276–281.Lo C.M., Cheung S.T., Lai C.L. et al. Liver transplantation in Asian patients with chronic hepatitis В using lamivudine prophylaxis // Ann. Surg. 2001. Vol. 233. Р. 276–281.Lok A.S., Heathcote E.J., Hoofnagle J.H. Management of hepatitis B: 2000 – summary of a workshop // Gastroenterology. 2001. Vol. 120. Р. 1828–1853.Lok A.S., Heathcote E.J., Hoofnagle J.H. Management of hepatitis B: 2000 – summary of a workshop // Gastroenterology. 2001. Vol. 120. Р. 1828–1853.Markowitz J.S., Martin P., Conrad A.J. et al. Prophylaxis against hepatitis B recurrence following liver transplanta- tion using combination lamivudine and hepatitis B immune globulin // Hepatology. 1998. Vol. 28. Р. 585–589.Markowitz J.S., Martin P., Conrad A.J. et al. Prophylaxis against hepatitis B recurrence following liver transplanta- tion using combination lamivudine and hepatitis B immune globulin // Hepatology. 1998. Vol. 28. Р. 585–589.McGory R.W., Ishitani M.B., Oliveira W.M. et al. Improved outcome of orthotopic liver transplantation for chronic he- patitis B cirrhosis with aggressive passive immunization // Transplantation. 1996. Vol. 61. Р. 1358–1364.McGory R.W., Ishitani M.B., Oliveira W.M. et al. Improved outcome of orthotopic liver transplantation for chronic he- patitis B cirrhosis with aggressive passive immunization // Transplantation. 1996. Vol. 61. Р. 1358–1364.Mutimer D., Dusheiko G., Barrett C. et al. Lamivudine wit- hout HBIg for prevention of graft reinfection by hepatitis B: long-term follow-up // Transplantation. 2000. Vol. 70. Р. 809–815.Mutimer D., Dusheiko G., Barrett C. et al. Lamivudine wit- hout HBIg for prevention of graft reinfection by hepatitis B: long-term follow-up // Transplantation. 2000. Vol. 70. Р. 809–815.Mutimer D., Pillay D., Dragon E. et al. High pre-treatment serum hepatitis В virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation // J. Hepatol. 1999. Vol. 30. Р. 715–721.Mutimer D., Pillay D., Dragon E. et al. High pre-treatment serum hepatitis В virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation // J. Hepatol. 1999. Vol. 30. Р. 715–721.Nevin Yilmaz, Mitchell L. Shiffman, R. Todd Stravitz et al. Prophylaxis Against Recurrance of Hepatitis B Virus After Liver Transplantation: A Retrospective Analysis Spanning 20 Years // J. Liver International. January 2008. Vol. 28 (1). Р. 72–78.Nevin Yilmaz, Mitchell L. Shiffman, R. Todd Stravitz et al. Prophylaxis Against Recurrance of Hepatitis B Virus After Liver Transplantation: A Retrospective Analysis Spanning 20 Years // J. Liver International. January 2008. Vol. 28 (1). Р. 72–78.Patterson S.J., Angus P.W. Post-liver transplant hepatitis B prophylaxis: the role of oral nucleos(t)ide analogues // Current opinion in organ transplantation. 2009. Vol. 14. Р. 225–230.Patterson S.J., Angus P.W. Post-liver transplant hepatitis B prophylaxis: the role of oral nucleos(t)ide analogues // Current opinion in organ transplantation. 2009. Vol. 14. Р. 225–230.Pellicelli A.M., Barbaro G., Barbarini G. et al. Efficacy of Entecavir as rescue therapy in lamivudine-resistant patients with HBV liver cirrhosis and waiting for orthotopic liver transplantation, 59th AASLD Meeting, October 31 – No- vember 4, 2008, San Francisco, USA // Hepatology. 2008. Vol. 48: 4 (suppl.). Р. 701A (abstract 885).Pellicelli A.M., Barbaro G., Barbarini G. et al. Efficacy of Entecavir as rescue therapy in lamivudine-resistant patients with HBV liver cirrhosis and waiting for orthotopic liver transplantation, 59th AASLD Meeting, October 31 – No- vember 4, 2008, San Francisco, USA // Hepatology. 2008. Vol. 48: 4 (suppl.). Р. 701A (abstract 885).Perrillo R.P., Wright T., Rakela J. et al. A multicenter United States-Canadian trial to assess lamivudine monotherapy be- fore and after liver transplantation for chronic hepatitis B // Hepatology. 2001. Vol. 33. Р. 424–432.Perrillo R.P., Wright T., Rakela J. et al. A multicenter United States-Canadian trial to assess lamivudine monotherapy be- fore and after liver transplantation for chronic hepatitis B // Hepatology. 2001. Vol. 33. Р. 424–432.Prieto M., Gomez M., Berenguer M. et al. De novo he- patitis B after liver transplantation from hepatitis B core antibody–positive donors in an area with high prevalence of anti-HBc positivity in the donor population // Liver Transpl. 2001. No 7. Р. 51–58.Prieto M., Gomez M., Berenguer M. et al. De novo he- patitis B after liver transplantation from hepatitis B core antibody–positive donors in an area with high prevalence of anti-HBc positivity in the donor population // Liver Transpl. 2001. No 7. Р. 51–58.Roche B., Samuel D., Gigou M. et al. De novo and apparent de novo hepatitis B virus infection after liver transplanta- tion // J. Hepatol. 1997. Vol. 26 (3). Р. 517–526.Roche B., Samuel D., Gigou M. et al. De novo and apparent de novo hepatitis B virus infection after liver transplanta- tion // J. Hepatol. 1997. Vol. 26 (3). Р. 517–526.Roque-Afonso A.M., Feray C., Samuel D. et al. Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBC positive donors // Gut. 2002. Vol. 50 (1). Р. 95–99.Roque-Afonso A.M., Feray C., Samuel D. et al. Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBC positive donors // Gut. 2002. Vol. 50 (1). Р. 95–99.Samuel D., Bismuth A., Mathieu D. et al. Passive immuno- prophylaxis after liver transplantation in HBs-Ag-positive patients // Lancet. 1991. Vol. 337. Р. 813–815.Samuel D., Bismuth A., Mathieu D. et al. Passive immuno- prophylaxis after liver transplantation in HBs-Ag-positive patients // Lancet. 1991. Vol. 337. Р. 813–815.Samuel D., Muller M., Alexander G. et al. Liver transplan- tation in European patients with the hepatitis B surface an- tigen // N. Engl. J. Med. 1993. Vol. 329. Р. 1842–1847.Samuel D., Muller M., Alexander G. et al. Liver transplan- tation in European patients with the hepatitis B surface an- tigen // N. Engl. J. Med. 1993. Vol. 329. Р. 1842–1847.Sanchez-Fueyo A., Rimola A., Grande L. et al. Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: A new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation // He- patology. 2000. Vol. 31. Р. 496–501.Sanchez-Fueyo A., Rimola A., Grande L. et al. Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: A new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation // He- patology. 2000. Vol. 31. Р. 496–501.Seehofer D., Rayes N., Berg T. et al. Lamivudine as first- and second-line treatment of hepatitis B infection after liver transplantation // Transpl. Int. 2000. Vol. 13. Р. 290–296.Seehofer D., Rayes N., Berg T. et al. Lamivudine as first- and second-line treatment of hepatitis B infection after liver transplantation // Transpl. Int. 2000. Vol. 13. Р. 290–296.Segovia R., Sanchez-Fueyo A., Rimola A. et al. Evidence of serious graft damage induced by de novo hepatitis B virus infection after liver transplantation // Liver Transpl. 2001. No 7. Р. 106–112.Segovia R., Sanchez-Fueyo A., Rimola A. et al. Evidence of serious graft damage induced by de novo hepatitis B virus infection after liver transplantation // Liver Transpl. 2001. No 7. Р. 106–112.Su W.J., Ho M.C., Ni Y.H. et al. High-titer antibody to he- patitis B surface antigen before liver transplantation can prevent de novo hepatitis B infection // J. Pediatr. Gastroen- terol. Nutr. 2009. Vol. 48 (2). Р. 203–208.Su W.J., Ho M.C., Ni Y.H. et al. High-titer antibody to he- patitis B surface antigen before liver transplantation can prevent de novo hepatitis B infection // J. Pediatr. Gastroen- terol. Nutr. 2009. Vol. 48 (2). Р. 203–208.Toniutto P., Fumo E., Caldato M. et al. Favourable outcome of adefovir-dipivoxil treatment in acute de novo hepatitis B after liver transplantation // Transplantation. 2004. Vol. 15; 77 (3). Р. 472–473.Toniutto P., Fumo E., Caldato M. et al. Favourable outcome of adefovir-dipivoxil treatment in acute de novo hepatitis B after liver transplantation // Transplantation. 2004. Vol. 15; 77 (3). Р. 472–473.Uemoto S., Sugiyama K., Marusawa H. et al. Transmission of hepatitis B virus from hepatitis B core antibody-positive donors in living related liver transplants // Transplantation. 1998. Vol. 65 (4). Р. 494–499.Uemoto S., Sugiyama K., Marusawa H. et al. Transmission of hepatitis B virus from hepatitis B core antibody-positive donors in living related liver transplants // Transplantation. 1998. Vol. 65 (4). Р. 494–499.Umeda M., Marusawa H., Ueda M. et al. Beneficial effects of short-term lamivudine treatment for de novo hepatitis B virus reactivation after liver transplantation // Am. J. Trans- plant. 2006. Vol. 6 (11). Р. 2680–2685.Umeda M., Marusawa H., Ueda M. et al. Beneficial effects of short-term lamivudine treatment for de novo hepatitis B virus reactivation after liver transplantation // Am. J. Trans- plant. 2006. Vol. 6 (11). Р. 2680–2685.Villeneuve J.P., Condreay L.D., Willems B. et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B // Hepatology. 2000. Vol. 31. Р. 207–210.Villeneuve J.P., Condreay L.D., Willems B. et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B // Hepatology. 2000. Vol. 31. Р. 207–210.Wachs M.E., Amend W.J., Ascher N.L. et al. The risk of transmission of hepatitis B from HBsAg(–), HBcAb(+), HBIgM(–) organ donors // Transplantation. 1995. Vol. 59 (2). Р. 230–234.Wachs M.E., Amend W.J., Ascher N.L. et al. The risk of transmission of hepatitis B from HBsAg(–), HBcAb(+), HBIgM(–) organ donors // Transplantation. 1995. Vol. 59 (2). Р. 230–234.Yao F.Y., Bass N.M. Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepati- tis В infection // J. Hepatоl. 2000. Vol. 33. Р. 301–307.Yao F.Y., Bass N.M. Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepati- tis В infection // J. Hepatоl. 2000. Vol. 33. Р. 301–307.Yao F.Y., Terrault N.A., Freise C. et al. Lamivudine treat- ment is beneficial in patients with severely decompensa- ted cirrhosis and actively replicating hepatitis В infection awaiting liver transplantation: a comparative study using a matched, untreated cohor // Hepatology. 2001. Vol. 34. Р. 411–416.Yao F.Y., Terrault N.A., Freise C. et al. Lamivudine treat- ment is beneficial in patients with severely decompensa- ted cirrhosis and actively replicating hepatitis В infection awaiting liver transplantation: a comparative study using a matched, untreated cohor // Hepatology. 2001. Vol. 34. Р. 411–416.Zheng S., Chen Y., Liang T. et al. Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B Immunoglobulin prophylaxis // Liver Transpl. 2006. Vol. 12. Р. 253–258.Zheng S., Chen Y., Liang T. et al. Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B Immunoglobulin prophylaxis // Liver Transpl. 2006. Vol. 12. Р. 253–258.

The authors declare that there are no conflicts of interest present.